Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JZJ Chain DrugstoreSHSE:605266 -1.38%78 EBITDA Margin % is 3.35% as of Mar. 2026, which is 66% below its 10-year median of 9.90. GuruFocus rates SHSE:605266 with a GF Score™ of 78/100 and a GF Value™ of ¥23.52 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 662 Healthcare Providers & Services companies, JZJ Chain Drugstore ranks worse than 67.37% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JZJ Chain Drugstore EBITDA Margin % Related Terms
JZJ Chain Drugstore EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for JZJ Chain Drugstore's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, JZJ Chain Drugstore's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JZJ Chain Drugstore EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, JZJ Chain Drugstore's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JZJ Chain Drugstore's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JZJ Chain Drugstore (SHSE:605266) has a EBITDA Margin % of 3.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JZJ Chain Drugstore and its competitors. This is 66% below median its historical median of 9.90. Over the past decade, JZJ Chain Drugstore's EBITDA Margin % has ranged from 3.76 to 17.00. According to the industry distribution chart, JZJ Chain Drugstore ranks #446 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 67.4%.
Is JZJ Chain Drugstore's EBITDA Margin % too high?
JZJ Chain Drugstore's current EBITDA Margin % of 3.35% is 66% below median its 10-year median of 9.90. Over the past 10 years, this metric has ranged from a low of 3.76 to a high of 17.00. The Healthcare Providers & Services industry median EBITDA Margin % is 10.25. JZJ Chain Drugstore's value of 3.35% is 67.3% below this industry median. Based on the distribution chart, JZJ Chain Drugstore ranks #446 out of 662 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, JZJ Chain Drugstore has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JZJ Chain Drugstore's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, JZJ Chain Drugstore ranks #446 out of 662 companies for EBITDA Margin %. This places JZJ Chain Drugstore in the lower half of its industry. The industry median EBITDA Margin % is 10.25. JZJ Chain Drugstore's value of 3.35% is 67.3% below this benchmark. Historically, JZJ Chain Drugstore's own EBITDA Margin % has ranged from 3.76 to 17.00 over the past decade. While the company's 10-year median is 9.90 vs. the industry median of 10.25, JZJ Chain Drugstore has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.25, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JZJ Chain Drugstore's current EBITDA Margin % of 3.35% is 67.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JZJ Chain Drugstore and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JZJ Chain Drugstore's current EBITDA Margin % is 3.35%, which is 66% below median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JZJ Chain Drugstore stock overvalued right now?
Based on GuruFocus' analysis, JZJ Chain Drugstore (SHSE:605266) is currently considered Possible Value Trap. The stock's GF Value™ is ¥23.52, compared to a current price of ¥15.68 — trading 33.3% below its estimated fair value. The current EBITDA Margin % is 3.35%, which is 66% below median its 10-year median of 9.90 and 67.3% below the Healthcare Providers & Services industry median of 10.25. JZJ Chain Drugstore's overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JZJ Chain Drugstore (SHSE:605266), the current EBITDA Margin % is 3.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JZJ Chain Drugstore (SHSE:605266) Overvalued in 2026?
Based on GuruFocus' analysis, JZJ Chain Drugstore stock appears to be undervalued.
The current stock price of ¥15.68 is trading 33.3% below its estimated GF Value™ of ¥23.52.
GuruFocus considers JZJ Chain Drugstore to be Possible Value Trap.
Key valuation signals for SHSE:605266:
EBITDA Margin %: 3.35% (66% below median its 10-year median of 9.90)
GF Value™: ¥23.52 vs. price of ¥15.68 (33.3% below fair value)
Industry Position: 67.3% below the Healthcare Providers & Services median (#446 of 662)
No single metric tells the full story. See the SHSE:605266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JZJ Chain Drugstore Corp is engaged in the retail chain business of health products such as medicines, health foods, personal care products, household health products, convenience foods, and daily consumables and provides related professional services.
78GF Score
Get the complete analysis for SHSE:605266
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605266 has been successfully added to your 
